Replies to post #405834 on NorthWest Biotherapeutics Inc (NWBO)

[Horseb4CarT]

Wouldn’t DCVax-L have been produced for the phase 3 trial for UK and EU patients in the years prior to the end of the phase 3 trial ?

Also, Cognate was holding a lot of nwbo shares since they got payment in nwbo shares along the earlier days.

I believe nwbo (or was it LP) got those Cognate owned nwbo shares back as part of Cognate’s management buyout of Cognate. So Advent being spun out to Toucan might also have been a part of Cognate’s buyout to become a separate company that down the road was bought out by CRL for a pretty penny.

So there were a lot of moving pieces, however that doesn’t equate to improprieties.

[biosectinvestor]

Please quantify payments to Advent, not Cognate.

First of all, creating a factory and delivering product has costs, so please quantify what payments are for what.

I find your numbers questionable in terms of where they went and what they paid for.

So you’re going to have to do better than that.

[kabunushi]

Over the last 5 years, NWBO has paid Advent about $30M (not counting the spend for Sawston).

Exw, where did you get this number? The payments to Advent have been clearly reported every year because they report all payments to related parties. I looked back to 2017 I saw a total of $25M but that includes some millions paid related to Sawston, don't know if we can be sure of exactly how many millions.

I'd really like to know what backing data you cite because I just don't see it. I think NWBO was paying a lot largely because they had to equipment effectively reserved because they needed to be prepared for trial patients and as they do now, they needed to ensure that not having guaranteed production available they would obviously have trouble getting approved on that basis and might be shunned by investors even if the trial results are really good. They ended up not needing all they had reserved. I know they settle with Cognate for some rebates but I don't remember getting any rollback from advent.